Dendritic cells in cancer immunotherapy: Vaccines or autologous transplants?

Immunologic Research

Volumn 50, Issue 2-3, 2011, Pages 235-247

  Kalinski, Pawel ^a,b,c   Edington, Howard ^a,b,c   Zeh, Herbert J ^a,b,c   Okada, Hideho ^b,c   Butterfield, Lisa H ^a,b,c   Kirkwood, John M ^a,b,c   Bartlett, David L ^a,b,c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Cancer; Chemokine receptors; Chemokines; CTL; Cytokines; Dendritic cells; IL 12; Immunotherapy; NK; Th1; Treg; Vaccines

Indexed keywords

CANCER VACCINE; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; CYCLOOXYGENASE 2; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A2 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 6; IPILIMUMAB; PEGINTERFERON ALPHA2B; PROVENGE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ADOPTIVE TRANSFER; ADVANCED CANCER; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOTRANSPLANTATION; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL INTERACTION; CELL MATURATION; CELL MIGRATION; CROSS PRESENTATION; DENDRITIC CELL; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; INNATE IMMUNITY; LYMPH NODE; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MYELOID DENDRITIC CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; PROSTATE CANCER; REGULATORY T LYMPHOCYTE; SHELF LIFE; T LYMPHOCYTE ACTIVATION; TUMOR CELL;

ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPH NODES; NEOPLASMS; T-LYMPHOCYTES;

EID: 79961170539     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-011-8224-z     Document Type: Article

References (200)

1. A Jemal F Bray MM Center J Ferlay E Ward D Forman 2011 Global cancer statistics CA Cancer J Clin 61 2 69 90 21296855
2. WB Coley 1910 The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the Streptococcus erysipelas and the Bacillus prodigiosus) Proc R Soc Med 3 Surg Sect 1 48
3. HC Nauts WE Swift BL Coley 1946 The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M.D., reviewed in the light of modern research Cancer Res 6 205 216 21018724 1:STN:280: DyaH28%2Fjs1yhuw%3D%3D
4. Y Wu JE Rosenberg ME Taplin 2011 Novel agents and new therapeutics in castration-resistant prostate cancer Curr Opin Oncol 23 3 290 296 21311328 1:CAS:528:DC%2BC3MXks1Whsrk%3D
5. EJ Small PF Schellhammer CS Higano, et al. 2006 Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer J Clin Oncol 24 19 3089 3094 16809734 1:CAS:528:DC%2BD28XnslKhs7g%3D (Pubitemid 46638945)
6. AL Harzstark EJ Small 2007 Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge) Expert Opin Biol Ther 7 8 1275 1280 17696825 1:CAS:528:DC%2BD2sXovFyju74%3D (Pubitemid 47305251)
7. Rethinking therapeutic cancer vaccines. Nat Rev Drug Discov. 2009;8(9):685-6.
8. CG Drake 2009 Immunotherapy for prostate cancer: walk, don't run J Clin Oncol 27 25 4035 4037 19635998 1:CAS:528:DC%2BD1MXhtF2jtLzF
9. CS Higano PF Schellhammer EJ Small, et al. 2009 Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer Cancer 115 16 3670 3679 19536890 1:CAS:528:DC%2BD1MXhtVOnurbJ
10. K Lassi NA Dawson 2009 Emerging therapies in castrate-resistant prostate cancer Curr Opin Oncol 21 3 260 265 19363343 1:CAS:528:DC%2BD1MXktl2jurY%3D
11. AL Nelson E Dhimolea JM Reichert 2010 Development trends for human monoclonal antibody therapeutics Nat Rev Drug Discov 9 10 767 774 20811384 1:CAS:528:DC%2BC3cXhtFSisLnO
12. J Schlom PM Arlen JL Gulley 2007 Cancer vaccines: moving beyond current paradigms Clin Cancer Res 13 13 3776 3782 17606707 1:CAS:528: DC%2BD2sXntFymsbw%3D (Pubitemid 47037581)
13. D Bell P Chomarat D Broyles, et al. 1999 In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas J Exp Med 190 10 1417 1426 10562317 1:CAS:528:DyaK1MXnsVams7g%3D
14. K Toriyama DR Wen E Paul AJ Cochran 1993 Variations in the distribution, frequency, and phenotype of Langerhans cells during the evolution of malignant melanoma of the skin J Invest Dermatol 100 3 269S 273S 7680054 1:STN:280:DyaK3s7nvFOnsA%3D%3D (Pubitemid 23083171)
15. AJ Troy KL Summers PJ Davidson CH Atkinson DN Hart 1998 Minimal recruitment and activation of dendritic cells within renal cell carcinoma Clin Cancer Res 4 3 585 593 9533525 1:STN:280:DyaK1c7pt1WqtA%3D%3D (Pubitemid 28193556)
16. W Zou V Machelon A Coulomb-L'Hermin, et al. 2001 Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells Nat Med 7 12 1339 1346 11726975 1:CAS:528:DC%2BD3MXovFKmsLc%3D (Pubitemid 34007939)
17. B Almand JR Resser B Lindman, et al. 2000 Clinical significance of defective dendritic cell differentiation in cancer Clin Cancer Res 6 5 1755 1766 10815894 1:STN:280:DC%2BD3cvhtVOhsw%3D%3D (Pubitemid 30305068)
18. S Della Bella M Gennaro M Vaccari, et al. 2003 Altered maturation of peripheral blood dendritic cells in patients with breast cancer Br J Cancer 89 8 1463 1472 14562018 1:CAS:528:DC%2BD3sXotFeks7c%3D (Pubitemid 37386601)
19. K Shimizu Y Kurosawa M Taniguchi RM Steinman S Fujii 2007 Cross-presentation of glycolipid from tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell mediated immunity via dendritic cells J Exp Med 204 11 2641 2653 17923500 1:CAS:528: DC%2BD2sXht1KnurjJ (Pubitemid 350063944)
20. RM Steinman JC Adams ZA Cohn 1975 Identification of a novel cell type in peripheral lymphoid organs of mice IV. Identification and distribution in mouse spleen J Exp Med 141 4 804 820 1127378 1:STN:280:DyaE2M7lt1KnsA%3D%3D
21. RM Steinman ZA Cohn 1973 Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution J Exp Med 137 5 1142 1162 4573839 1:STN:280:DyaE3s7ntFejsw%3D%3D
22. RM Steinman ZA Cohn 1974 Identification of a novel cell type in peripheral lymphoid organs of mice. II. Functional properties in vitro J Exp Med 139 2 380 397 4589990 1:STN:280:DyaE2c%2Fos1ahtA%3D%3D
23. RM Steinman DS Lustig ZA Cohn 1974 Identification of a novel cell type in peripheral lymphoid organs of mice. 3. Functional properties in vivo J Exp Med 139 6 1431 1445 4598015 1:STN:280:DyaE2c7mvVGktw%3D%3D
24. S Fujii K Shimizu H Hemmi, et al. 2006 Glycolipid alpha-C- galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice Proc Natl Acad Sci USA 103 30 11252 11257 16844772 1:CAS:528:DC%2BD28XnvValtbs%3D (Pubitemid 44156505)
25. P Kalinski CM Hilkens EA Wierenga ML Kapsenberg 1999 T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal Immunol Today 20 12 561 567 10562707 1:CAS:528:DyaK1MXns1Sgurk%3D
26. S Markowicz EG Engleman 1990 Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheral blood dendritic cells in vitro J Clin Invest 85 3 955 961 2179270 1:STN:280: DyaK3c7oslSqtw%3D%3D (Pubitemid 20087502)
27. F Sallusto A Lanzavecchia 1994 Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha J Exp Med 179 4 1109 1118 8145033 1:CAS:528:DyaK2cXhs1Wjurg%3D
28. C Caux C Dezutter-Dambuyant D Schmitt J Banchereau 1992 GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells Nature 360 6401 258 261 1279441 1:CAS:528:DyaK3sXitVOgtw%3D%3D
29. P Kalinski JH Schuitemaker CM Hilkens EA Wierenga ML Kapsenberg 1999 Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells J Immunol 162 6 3231 3236 10092774 1:CAS:528:DyaK1MXhvV2rtLs%3D (Pubitemid 29313569)
30. PL Vieira EC de Jong EA Wierenga ML Kapsenberg P Kalinski 2000 Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction J Immunol 164 9 4507 4512 10779751 1:CAS:528:DC%2BD3cXivFWmt74%3D (Pubitemid 30238046)
31. P Kalinski JH Schuitemaker CM Hilkens ML Kapsenberg 1998 Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a + CD83 + dendritic cells: the levels of IL-12 are determined during the final dendritic cell maturation and are resistant to further modulation J Immunol 161 6 2804 2809 9743339 1:CAS:528:DyaK1cXmtVKitrk%3D (Pubitemid 28425700)
32. FO Nestle S Alijagic M Gilliet, et al. 1998 Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells Nat Med 4 3 328 332 9500607 1:CAS:528:DyaK1cXhs1Kisrc%3D (Pubitemid 28144092)
33. FO Nestle A Farkas C Conrad 2005 Dendritic-cell-based therapeutic vaccination against cancer Curr Opin Immunol 17 2 163 169 15766676 1:CAS:528:DC%2BD2MXit1ChtL4%3D (Pubitemid 40343103)
34. EG Engleman 1996 Dendritic cells in the treatment of cancer Biol Blood Marrow Transplant 2 3 115 117 9199753 1:STN:280:DyaK2szktlWhtg%3D%3D
35. FJ Hsu C Benike F Fagnoni, et al. 1996 Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells Nat Med 2 1 52 58 8564842 1:CAS:528:DyaK28XivVSnuw%3D%3D (Pubitemid 26028073)
36. J Banchereau AK Palucka 2005 Dendritic cells as therapeutic vaccines against cancer Nat Rev Immunol 5 4 296 306 15803149 1:CAS:528: DC%2BD2MXivVaku7c%3D (Pubitemid 40516155)
37. JN Blattman PD Greenberg 2004 Cancer immunotherapy: a treatment for the masses Science 305 5681 200 205 15247469 1:CAS:528:DC%2BD2cXlsV2gtrw%3D (Pubitemid 38886725)
38. CG Figdor IJ de Vries WJ Lesterhuis CJ Melief 2004 Dendritic cell immunotherapy: mapping the way Nat Med 10 5 475 480 15122249 1:CAS:528:DC%2BD2cXjsF2jtLs%3D (Pubitemid 38667904)
39. E Gilboa 2004 The promise of cancer vaccines Nat Rev Cancer 4 5 401 411 15122211 1:CAS:528:DC%2BD2cXjsFSlu7s%3D (Pubitemid 38579486)
40. SA Rosenberg JC Yang NP Restifo 2004 Cancer immunotherapy: moving beyond current vaccines Nat Med 10 9 909 915 15340416 1:CAS:528:DC%2BD2cXntFSktL0%3D (Pubitemid 39273730)
41. PK Srivastava 2006 Therapeutic cancer vaccines Curr Opin Immunol 18 2 201 205 16464565 1:CAS:528:DC%2BD28XitVaksb4%3D (Pubitemid 43327303)
42. J Schlom JL Gulley PM Arlen 2008 Paradigm shifts in cancer vaccine therapy Exp Biol Med (Maywood) 233 5 522 534 1:CAS:528:DC%2BD1cXlsF2hsbo%3D (Pubitemid 351657353)
43. PH Patel DR Kockler 2008 Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer Ann Pharmacother 42 1 91 98 18094343
44. L Pilla R Patuzzo L Rivoltini, et al. 2006 A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients Cancer Immunol Immunother 55 8 958 968 16215718 1:CAS:528: DC%2BD28XjvFGisb4%3D (Pubitemid 43673585)
45. GE Peoples JP Holmes MT Hueman, et al. 2008 Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02 Clin Cancer Res 14 3 797 803 18245541 1:CAS:528:DC%2BD1cXhsFykt7o%3D (Pubitemid 351231162)
46. H Okada P Kalinski R Ueda, et al. 2011 Induction of CD8 + T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma J Clin Oncol 29 3 330 336 21149657 1:CAS:528:DC%2BC3MXit1yhurs%3D
47. RM Steinman J Banchereau 2007 Taking dendritic cells into medicine Nature 449 7161 419 426 17898760 1:CAS:528:DC%2BD2sXhtV2is7%2FI (Pubitemid 47509552)
48. A Mantovani P Romero AK Palucka FM Marincola 2008 Tumour immunity: effector response to tumour and role of the microenvironment Lancet 371 9614 771 783 18275997 1:CAS:528:DC%2BD1cXislWitr0%3D
49. CJ Melief 2008 Cancer immunotherapy by dendritic cells Immunity 29 3 372 383 18799145 1:CAS:528:DC%2BD1cXhtF2jtLvF
50. EL Pearce H Shen 2006 Making sense of inflammation, epigenetics, and memory CD8 + T-cell differentiation in the context of infection Immunol Rev 211 197 202 16824128 1:CAS:528:DC%2BD28Xot1Grsb4%3D (Pubitemid 43882972)
51. AM Cooper SA Khader 2008 The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis Immunol Rev 226 191 204 19161425 1:CAS:528:DC%2BD1MXhsFGls7%2FO
52. JT Harty VP Badovinac 2002 Influence of effector molecules on the CD8(+) T cell response to infection Curr Opin Immunol 14 3 360 365 11973135 1:CAS:528:DC%2BD38XjtVeitLw%3D (Pubitemid 34327979)
53. EM van Leeuwen J Sprent CD Surh 2009 Generation and maintenance of memory CD4(+) T Cells Curr Opin Immunol 21 2 167 172 19282163
54. JS Haring VP Badovinac JT Harty 2006 Inflaming the CD8 + T cell response Immunity 25 1 19 29 16860754 1:CAS:528:DC%2BD28XotVeqtLk%3D
55. F Sallusto J Geginat A Lanzavecchia 2004 Central memory and effector memory T cell subsets: function, generation, and maintenance Annu Rev Immunol 22 745 763 15032595 1:CAS:528:DC%2BD2cXktlOgsb8%3D (Pubitemid 38680440)
56. F Sallusto CR Mackay A Lanzavecchia 2000 The role of chemokine receptors in primary, effector, and memory immune responses Annu Rev Immunol 18 593 620 10837070 1:CAS:528:DC%2BD3cXjs1Gmtr0%3D (Pubitemid 30365392)
57. D Hartl S Krauss-Etschmann B Koller, et al. 2008 Infiltrated neutrophils acquire novel chemokine receptor expression and chemokine responsiveness in chronic inflammatory lung diseases J Immunol 181 11 8053 8067 19017998 1:CAS:528:DC%2BD1cXhtl2gsL3J
58. A Mantovani P Allavena S Sozzani A Vecchi M Locati A Sica 2004 Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors Semin Cancer Biol 14 3 155 160 15246050 1:CAS:528:DC%2BD2cXjvVemsb8%3D (Pubitemid 38586740)
59. U Mrowietz U Schwenk S Maune, et al. 1999 The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice Br J Cancer 79 7-8 1025 1031 10098731 1:CAS:528:DyaK1MXhvVKqtL4%3D (Pubitemid 29087870)
60. AS Payne LA Cornelius 2002 The role of chemokines in melanoma tumor growth and metastasis J Invest Dermatol 118 6 915 922 12060384 1:CAS:528:DC%2BD38XlsV2rsr8%3D (Pubitemid 34639168)
61. RD Bonfil S Chinni R Fridman HR Kim ML Cher 2007 Proteases, growth factors, chemokines, and the microenvironment in prostate cancer bone metastasis Urol Oncol 25 5 407 411 17826661 1:CAS:528:DC%2BD2sXhtVWhtr3M (Pubitemid 47362762)
62. D Raman PJ Baugher YM Thu A Richmond 2007 Role of chemokines in tumor growth Cancer Lett 256 2 137 165 17629396 1:CAS:528:DC%2BD2sXhtVOisLrE (Pubitemid 47418345)
63. TC Walser AM Fulton 2004 The role of chemokines in the biology and therapy of breast cancer Breast Dis 20 137 143 15687714 1:CAS:528: DC%2BD2cXhtVahsLjP (Pubitemid 39600453)
64. W Zou 2006 Regulatory T cells, tumour immunity and immunotherapy Nat Rev Immunol 6 4 295 307 16557261 1:CAS:528:DC%2BD28XivVyru7k%3D
65. TJ Curiel G Coukos L Zou, et al. 2004 Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nat Med 10 9 942 949 15322536 1:CAS:528:DC%2BD2cXntFSkt7g%3D (Pubitemid 39273735)
66. J Vieweg Z Su P Dahm S Kusmartsev 2007 Reversal of tumor-mediated immunosuppression Clin Cancer Res 13 2 Pt 2 727s 732s 17255301 1:CAS:528:DC%2BD2sXoslSqtg%3D%3D
67. DK Banerjee MV Dhodapkar E Matayeva RM Steinman KM Dhodapkar 2006 Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients Blood 108 8 2655 2661 16763205 1:CAS:528:DC%2BD28XhtFWgtL%2FO
68. GA Rabinovich D Gabrilovich EM Sotomayor 2007 Immunosuppressive strategies that are mediated by tumor cells Annu Rev Immunol 25 267 296 17134371 1:CAS:528:DC%2BD2sXltlagu7c%3D (Pubitemid 46697910)
69. D Gabrilovich 2004 Mechanisms and functional significance of tumour-induced dendritic-cell defects Nat Rev Immunol 4 12 941 952 15573129 1:CAS:528:DC%2BD2cXhtVarsb7P (Pubitemid 39620069)
70. D Gabrilovich V Pisarev 2003 Tumor escape from immune response: mechanisms and targets of activity Curr Drug Targets 4 7 525 536 14535653 1:CAS:528:DC%2BD3sXnsV2htbg%3D (Pubitemid 37139048)
71. B Almand JI Clark E Nikitina, et al. 2001 Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer J Immunol 166 1 678 689 11123353 1:CAS:528:DC%2BD3MXis1elsw%3D%3D (Pubitemid 32038493)
72. DI Gabrilovich MP Velders EM Sotomayor WM Kast 2001 Mechanism of immune dysfunction in cancer mediated by immature Gr-1 + myeloid cells J Immunol 166 9 5398 5406 11313376 1:CAS:528:DC%2BD3MXjtFyrtL0%3D (Pubitemid 32374159)
73. MR Young MA Wright Y Lozano, et al. 1997 Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34 + natural suppressor cells Int J Cancer 74 1 69 74 9036872 1:STN:280: DyaK2s7ovVartQ%3D%3D (Pubitemid 27157858)
74. K Uchida S Schneider JM Yochim, et al. 2005 Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy Clin Cancer Res 11 9 3363 3368 15867236 1:CAS:528:DC%2BD2MXjslOqt74%3D (Pubitemid 40627888)
75. C Williams RL Shattuck-Brandt RN DuBois 1999 The role of COX-2 in intestinal cancer Ann N Y Acad Sci 889 72 83 10668484 1:CAS:528: DC%2BD3cXnt1Snuw%3D%3D (Pubitemid 30040427)
76. T Inaba H Sano Y Kawahito, et al. 2003 Induction of cyclooxygenase-2 in monocyte/macrophage by mucins secreted from colon cancer cells Proc Natl Acad Sci USA 100 5 2736 2741 12598658 1:CAS:528:DC%2BD3sXitVait70%3D (Pubitemid 36297568)
77. LT Soumaoro H Uetake T Higuchi Y Takagi M Enomoto K Sugihara 2004 Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer Clin Cancer Res 10 24 8465 8471 15623626 1:CAS:528:DC%2BD2cXhtFGjs7rF (Pubitemid 40053411)
78. J Dannull Z Su D Rizzieri, et al. 2005 Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells J Clin Invest 115 12 3623 3633 16308572 1:CAS:528:DC%2BD2MXhtlSqtLjJ (Pubitemid 43121851)
79. S Yamazaki K Inaba KV Tarbell RM Steinman 2006 Dendritic cells expand antigen-specific Foxp3 + CD25 + CD4 + regulatory T cells including suppressors of alloreactivity Immunol Rev 212 314 329 16903923 1:CAS:528: DC%2BD28XpvFegtbo%3D (Pubitemid 44116717)
80. A Langenkamp M Messi A Lanzavecchia F Sallusto 2000 Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells Nat Immunol 1 4 311 316 11017102 1:CAS:528:DC%2BD3cXntlyjsbY%3D
81. A Camporeale A Boni G Iezzi, et al. 2003 Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes Cancer Res 63 13 3688 3694 12839960 1:CAS:528:DC%2BD3sXltVGru7g%3D (Pubitemid 36793053)
82. P Watchmaker E Berk R Muthuswamy, et al. 2010 Independent regulation of chemokine responsiveness and cytolytic function versus CD8 + T cell expansion by dendritic cells J Immunol 184 591 597 20018619 1:CAS:528:DC%2BC3cXhslCguw%3D%3D
83. IF Hermans DS Ritchie J Yang JM Roberts F Ronchese 2000 CD8 + T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity J Immunol 164 6 3095 3101 10706699 1:CAS:528: DC%2BD3cXhvVeksr0%3D (Pubitemid 30148970)
84. F Ronchese IF Hermans 2001 Killing of dendritic cells: a life cut short or a purposeful death? J Exp Med 194 5 F23 F26 11535638 1:CAS:528: DC%2BD3MXms1Khs7s%3D
85. J Yang SP Huck RS McHugh IF Hermans F Ronchese 2006 Perforin-dependent elimination of dendritic cells regulates the expansion of antigen-specific CD8 + T cells in vivo Proc Natl Acad Sci USA 103 1 147 152 16373503 1:CAS:528:DC%2BD28Xms12itA%3D%3D (Pubitemid 43076119)
86. Y Nakamura P Watchmaker J Urban, et al. 2007 Helper function of memory CD8 + T cells: heterologous CD8 + T cells support the induction of therapeutic cancer immunity Cancer Res 67 20 10012 10018 17942935 1:CAS:528: DC%2BD2sXhtFOnsLrK (Pubitemid 47621252)
87. P Watchmaker J Urban E Berk, et al. 2008 Memory CD8 + T cells protect dendritic cells from CTL killing J Immunol 180 3857 3865 18322193 1:CAS:528:DC%2BD1cXisl2js7c%3D
88. G Guarda M Hons SF Soriano, et al. 2007 L-selectin-negative CCR7- effector and memory CD8 + T cells enter reactive lymph nodes and kill dendritic cells Nat Immunol 8 7 743 752 17529983 1:CAS:528:DC%2BD2sXms1Wgtb0%3D (Pubitemid 46965350)
89. IJ De Vries DJ Krooshoop NM Scharenborg, et al. 2003 Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state Cancer Res 63 1 12 17 12517769 (Pubitemid 36070411)
90. IJ de Vries WJ Lesterhuis NM Scharenborg, et al. 2003 Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients Clin Cancer Res 9 14 5091 5100 14613986 (Pubitemid 37413557)
91. SM Barratt-Boyes CG Figdor 2004 Current issues in delivering DCs for immunotherapy Cytotherapy 6 2 105 110 15203986 1:STN:280:DC%2BD2czgt1Knsw%3D%3D (Pubitemid 38714806)
92. R Muthuswamy J Mueller-Berghaus U Haberkorn TA Reinhart D Schadendorf P Kalinski 2010 PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells Blood 116 9 1454 1459 20498301 1:CAS:528:DC%2BC3cXhtF2qsb%2FJ
93. WL Olszewski I Grzelak A Ziolkowska A Engeset 1995 Immune cell traffic from blood through the normal human skin to lymphatics Clin Dermatol 13 5 473 483 8665458 1:STN:280:DyaK283jtV2ksQ%3D%3D (Pubitemid 26073917)
94. H Galkowska WL Olszewski 1992 Immune events in skin. I. Spontaneous cluster formation of dendritic (veiled) cells and lymphocytes from skin lymph Scand J Immunol 35 6 727 734 1604244 1:STN:280:DyaK383psVOrtA%3D%3D
95. N Yawalkar CU Brand LR Braathen 1996 IL-12 gene expression in human skin-derived CD1a + dendritic lymph cells Arch Dermatol Res 288 2 79 84 8932585 1:CAS:528:DyaK28XitlKls7c%3D (Pubitemid 26071439)
96. CU Brand N Yawalkar T Hunziker LR Braathen 1997 Human skin lymph derived from irritant and allergic contact dermatitis: interleukin 10 is increased selectively in elicitation reactions Dermatology 194 3 221 228 9187837 1:STN:280:DyaK2szjtFGjtw%3D%3D (Pubitemid 27216033)
97. RE Hunger N Yawalkar LR Braathen CU Brand 2001 CD1a-positive dendritic cells transport the antigen DNCB intracellularly from the skin to the regional lymph nodes in the induction phase of allergic contact dermatitis Arch Dermatol Res 293 8 420 426 11686518 1:CAS:528:DC%2BD3MXotlGlu7s%3D (Pubitemid 32939423)
98. N Yawalkar CU Brand LR Braathen 1998 Interleukin-12 expression in human afferent lymph derived from the induction phase of allergic contact dermatitis Br J Dermatol 138 2 297 300 9602878 1:STN:280:DyaK1c3msFGrug%3D%3D (Pubitemid 28114135)
99. JM LaSalle DA Hafler 1994 T cell anergy FASEB J 8 9 601 608 8005388 1:CAS:528:DyaK2cXksFGgt7c%3D (Pubitemid 24198677)
100. JF Miller C Kurts J Allison H Kosaka F Carbone WR Heath 1998 Induction of peripheral CD8 + T-cell tolerance by cross-presentation of self antigens Immunol Rev 165 267 277 9850866 1:CAS:528:DyaK1cXotVKhtLg%3D (Pubitemid 28524217)
101. AV Gett F Sallusto A Lanzavecchia J Geginat 2003 T cell fitness determined by signal strength Nat Immunol 4 4 355 360 12640450 1:CAS:528:DC%2BD3sXitlyqs7o%3D (Pubitemid 36432318)
102. G Iezzi K Karjalainen A Lanzavecchia 1998 The duration of antigenic stimulation determines the fate of naive and effector T cells Immunity 8 1 89 95 9462514 1:CAS:528:DyaK1cXptVOrsg%3D%3D (Pubitemid 28097826)
103. G Iezzi E Scotet D Scheidegger A Lanzavecchia 1999 The interplay between the duration of TCR and cytokine signaling determines T cell polarization Eur J Immunol 29 12 4092 4101 10602020 1:CAS:528:DyaK1MXotVehsLY%3D
104. S Valitutti M Dessing K Aktories H Gallati A Lanzavecchia 1995 Sustained signaling leading to T cell activation results from prolonged T cell receptor occupancy. Role of T cell actin cytoskeleton J Exp Med 181 2 577 584 7836913 1:CAS:528:DyaK2MXjtFyhu7Y%3D
105. R Obst HM van Santen D Mathis C Benoist 2005 Antigen persistence is required throughout the expansion phase of a CD4(+) T cell response J Exp Med 201 10 1555 1565 15897273 1:CAS:528:DC%2BD2MXktlygu7g%3D (Pubitemid 40721001)
106. H Jusforgues-Saklani M Uhl N Blachere, et al. 2008 Antigen persistence is required for dendritic cell licensing and CD8 + T cell cross-priming J Immunol 181 5 3067 3076 18713977 1:CAS:528:DC%2BD1cXhtVSiu7rL
107. VE Schijns 2001 Induction and direction of immune responses by vaccine adjuvants Crit Rev Immunol 21 1-3 75 85 11642615 1:STN:280: DC%2BD3Mrmt1Ogug%3D%3D (Pubitemid 32959353)
108. Z Zhao KW Leong 1996 Controlled delivery of antigens and adjuvants in vaccine development J Pharm Sci 85 12 1261 1270 8961136 1:CAS:528: DyaK28Xms1CmtLs%3D (Pubitemid 27014177)
109. TW Kim CF Hung M Ling, et al. 2003 Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins J Clin Invest 112 1 109 117 12840065 1:CAS:528:DC%2BD3sXlt1KrtL8%3D (Pubitemid 38056382)
110. TH Kang JH Lee KH Noh, et al. 2007 Enhancing dendritic cell vaccine potency by combining a BAK/BAX siRNA-mediated antiapoptotic strategy to prolong dendritic cell life with an intracellular strategy to target antigen to lysosomal compartments Int J Cancer 120 8 1696 1703 17230516 1:CAS:528:DC%2BD2sXjtFOkt7s%3D (Pubitemid 46399356)
111. S Peng TW Kim JH Lee, et al. 2005 Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life Hum Gene Ther 16 5 584 593 15916483 1:CAS:528:DC%2BD2MXksVCqu7c%3D (Pubitemid 40740926)
112. H Ozawa W Ding H Torii, et al. 1999 Granulocyte-macrophage colony-stimulating factor gene transfer to dendritic cells or epidermal cells augments their antigen-presenting function including induction of anti-tumor immunity J Invest Dermatol 113 6 999 1005 10594743 1:CAS:528: DC%2BD3cXhtFGhsA%3D%3D (Pubitemid 30013344)
113. JF Arthur LH Butterfield MD Roth, et al. 1997 A comparison of gene transfer methods in human dendritic cells Cancer Gene Ther 4 1 17 25 9012447 1:CAS:528:DyaK2sXhtVeru7g%3D (Pubitemid 127672232)
114. J Banchereau RM Steinman 1998 Dendritic cells and the control of immunity Nature 392 6673 245 252 9521319 1:CAS:528:DyaK1cXitFWrsr8%3D (Pubitemid 28155090)
115. G Schuler B Schuler-Thurner RM Steinman 2003 The use of dendritic cells in cancer immunotherapy Curr Opin Immunol 15 2 138 147 12633662 1:CAS:528:DC%2BD3sXhvFaiu7w%3D (Pubitemid 36287518)
116. G Schuler RM Steinman 1997 Dendritic cells as adjuvants for immune-mediated resistance to tumors J Exp Med 186 8 1183 1187 9379142 1:CAS:528:DyaK2sXmvVejurs%3D (Pubitemid 27469012)
117. ML Kapsenberg 2003 Dendritic-cell control of pathogen-driven T-cell polarization Nat Rev Immunol 3 12 984 993 14647480 1:CAS:528: DC%2BD3sXpvFCgs74%3D (Pubitemid 37521540)
118. H Ikeda K Chamoto T Tsuji, et al. 2004 The critical role of type-1 innate and acquired immunity in tumor immunotherapy Cancer Sci 95 9 697 703 15471553 1:CAS:528:DC%2BD2cXpvFOgur0%3D (Pubitemid 39335087)
119. B Pulendran 2004 Modulating TH1/TH2 responses with microbes, dendritic cells, and pathogen recognition receptors Immunol Res 29 1-3 187 196 15181281 1:CAS:528:DC%2BD2cXlsFGiur8%3D (Pubitemid 38822408)
120. G Trinchieri 2003 Interleukin-12 and the regulation of innate resistance and adaptive immunity Nat Rev Immunol 3 2 133 146 12563297 1:CAS:528: DC%2BD3sXot12gug%3D%3D (Pubitemid 37328691)
121. K Palucka J Banchereau 2002 How dendritic cells and microbes interact to elicit or subvert protective immune responses Curr Opin Immunol 14 4 420 431 12088675 1:CAS:528:DC%2BD38XkslKitrg%3D (Pubitemid 34671243)
122. BJ Czerniecki PA Cohen M Faries S Xu JG Roros I Bedrosian 2001 Diverse functional activity of CD83 + monocyte-derived dendritic cells and the implications for cancer vaccines Crit Rev Immunol 21 1-3 157 178 11642602 1:CAS:528:DC%2BD3MXnvVCrur8%3D (Pubitemid 32959359)
123. P Kalinski M Moser 2005 Consensual immunity: success-driven development of T-helper-1 and T-helper-2 responses Nat Rev Immunol 5 3 251 260 15738955 1:CAS:528:DC%2BD2MXhslSjurc%3D (Pubitemid 40364826)
124. G Driessens L Gordower L Nuttin, et al. 2008 Therapeutic efficacy of antitumor dendritic cell vaccinations correlates with persistent Th1 responses, high intratumor CD8 + T cell recruitment and low relative regulatory T cell infiltration Cancer Immunol Immunother 57 12 1745 1756 18369621 1:CAS:528:DC%2BD1cXhtFCgu7vF
125. P Kalinski H Okada 2010 Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors Semin Immunol 22 3 173 182 20409732 1:CAS:528:DC%2BC3cXnsVart7g%3D
126. S Amigorena A Savina 2010 Intracellular mechanisms of antigen cross presentation in dendritic cells Curr Opin Immunol 22 1 109 117 20171863 1:CAS:528:DC%2BC3cXis1Shsro%3D
127. Y Ma L Aymeric C Locher G Kroemer L Zitvogel 2010 The dendritic cell-tumor cross-talk in cancer Curr Opin Immunol 23 1 146 152 20970973
128. JM Vyas AG Van der Veen HL Ploegh 2008 The known unknowns of antigen processing and presentation Nat Rev Immunol 8 8 607 618 18641646 1:CAS:528:DC%2BD1cXovV2gt74%3D
129. P van der Bruggen BJ Van den Eynde 2006 Processing and presentation of tumor antigens and vaccination strategies Curr Opin Immunol 18 1 98 104 16343880
130. Amigorena S, Savina A. Intracellular mechanisms of antigen cross presentation in dendritic cells. Curr Opin Immunol;22 (1):109-17.
131. E Segura JA Villadangos 2009 Antigen presentation by dendritic cells in vivo Curr Opin Immunol 21 1 105 110 19342210 1:CAS:528:DC%2BD1MXksVCntr4%3D
132. K Shortman WR Heath 2010 The CD8 + dendritic cell subset Immunol Rev 234 1 18 31 20193009 1:CAS:528:DC%2BC3cXjslarsbk%3D
133. AA Manfredi A Capobianco ME Bianchi P Rovere-Querini 2009 Regulation of dendritic- and T-cell fate by injury-associated endogenous signals Crit Rev Immunol 29 1 69 86 19348611 1:CAS:528:DC%2BD1MXmtVSrs70%3D
134. A Macagno M Gilliet F Sallusto A Lanzavecchia FO Nestle M Groettrup 1999 Dendritic cells up-regulate immunoproteasomes and the proteasome regulator PA28 during maturation Eur J Immunol 29 12 4037 4042 10602014 1:CAS:528: DyaK1MXotVehsLw%3D
135. A Lanzavecchia 1996 Mechanisms of antigen uptake for presentation Curr Opin Immunol 8 3 348 354 8794000 1:CAS:528:DyaK28Xktlegtrc%3D (Pubitemid 26229656)
136. F Sallusto M Cella C Danieli A Lanzavecchia 1995 Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products J Exp Med 182 2 389 400 7629501 1:CAS:528:DyaK2MXntFKhs70%3D
137. A Lopez-Albaitero R Mailliard T Hackman, et al. 2009 Maturation pathways of dendritic cells determine TAP1 and TAP2 levels and cross-presenting function J Immunother 32 5 465 473 19609238 1:CAS:528:DC%2BD1MXmtFKgsrs%3D
138. MV Dhodapkar RM Steinman M Sapp, et al. 1999 Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells J Clin Invest 104 2 173 180 10411546 1:CAS:528:DyaK1MXkslSmsbo%3D
139. GJ Adema IJ de Vries CJ Punt CG Figdor 2005 Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr Opin Immunol 17 2 170 174 15766677 1:CAS:528:DC%2BD2MXit1ChtL8%3D (Pubitemid 40343104)
140. A Bender M Sapp G Schuler RM Steinman N Bhardwaj 1996 Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood J Immunol Methods 196 2 121 135 8841451 1:CAS:528:DyaK28XlsFWrtLs%3D (Pubitemid 26306734)
141. A Reddy M Sapp M Feldman M Subklewe N Bhardwaj 1997 A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells Blood 90 9 3640 3646 9345048 1:CAS:528:DyaK2sXntVSqsr4%3D (Pubitemid 27473434)
142. H Jonuleit U Kuhn G Muller, et al. 1997 Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions Eur J Immunol 27 12 3135 3142 9464798 1:CAS:528:DyaK1cXisF2gug%3D%3D (Pubitemid 28018007)
143. T Luft M Jefford P Luetjens, et al. 2002 Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets Blood 100 4 1362 1372 12149219 1:CAS:528:DC%2BD38Xmt12itbk%3D (Pubitemid 34864293)
144. E Scandella Y Men S Gillessen R Forster M Groettrup 2002 Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells Blood 100 4 1354 1361 12149218 1:CAS:528:DC%2BD38Xmt12itbg%3D (Pubitemid 34864292)
145. D Schadendorf S Ugurel B Schuler-Thurner, et al. 2006 Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG Ann Oncol 17 4 563 570 16418308 1:STN:280:DC%2BD287mslSltA%3D%3D
146. P Kalinski PL Vieira JH Schuitemaker EC de Jong ML Kapsenberg 2001 Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer Blood 97 11 3466 3469 11369638 1:CAS:528:DC%2BD3MXktFOktLc%3D
147. R Muthuswamy J Urban JJ Lee TA Reinhart D Bartlett P Kalinski 2008 Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation Cancer Res 68 14 5972 5978 18632653 1:CAS:528:DC%2BD1cXovVCntrc%3D
148. LH Butterfield W Gooding TL Whiteside 2008 Development of a potency assay for human dendritic cells: IL-12p70 production J Immunother 31 1 89 100 18157016 1:CAS:528:DC%2BD2sXhsVGgtLzF (Pubitemid 351619408)
149. MA DeBenedette DM Calderhead IY Tcherepanova CA Nicolette DG Healey 2011 Potency of mature CD40L RNA electroporated dendritic cells correlates with IL-12 secretion by tracking multifunctional CD8(+)/CD28(+) cytotoxic T-cell responses in vitro J Immunother 34 1 45 57 21150712 1:CAS:528:DC%2BC3cXhsFGksr7M
150. L Zitvogel JI Mayordomo T Tjandrawan, et al. 1996 Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines J Exp Med 183 1 87 97 8551248 1:CAS:528:DyaK28XjsVChtA%3D%3D (Pubitemid 26028748)
151. L Zitvogel PD Robbins WJ Storkus, et al. 1996 Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors Eur J Immunol 26 6 1335 1341 8647214 1:CAS:528:DyaK28Xks1egt7w%3D (Pubitemid 26001070)
152. K Furumoto S Arii S Yamasaki, et al. 2000 Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses Int J Cancer 87 5 665 672 10925360 1:CAS:528: DC%2BD3cXlvFahtbc%3D (Pubitemid 30620409)
153. K Furumoto A Mori S Yamasaki, et al. 2002 Interleukin-12-gene transduction makes DCs from tumor-bearing mice an effective inducer of tumor-specific immunity in a peritoneal dissemination model Immunol Lett 83 1 13 20 12057850 1:CAS:528:DC%2BD38XktFKjurY%3D (Pubitemid 34607534)
154. Y Nishioka M Hirao PD Robbins MT Lotze H Tahara 1999 Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12 Cancer Res 59 16 4035 4041 10463604 1:CAS:528:DyaK1MXlsVOltbs%3D (Pubitemid 29393574)
155. N Okada S Iiyama Y Okada, et al. 2005 Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12 Cancer Gene Ther 12 1 72 83 15389286 1:CAS:528:DC%2BD2cXhtVOht77N (Pubitemid 39665245)
156. RE Redlinger Jr RB Mailliard EM Barksdale Jr 2003 Advanced neuroblastoma impairs dendritic cell function in adoptive immunotherapy J Pediatr Surg 38 6 857 862 12778381 (Pubitemid 36666278)
157. Y Satoh C Esche A Gambotto, et al. 2002 Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice J Exp Ther Oncol 2 6 337 349 12440225 1:CAS:528:DC%2BD38XovFaksL4%3D (Pubitemid 35265983)
158. T Shimizu A Berhanu RE Redlinger Jr S Watkins MT Lotze EM Barksdale Jr 2001 Interleukin-12 transduced dendritic cells induce regression of established murine neuroblastoma J Pediatr Surg 36 8 1285 1292 11479878 1:STN:280: DC%2BD3MvjtFylsw%3D%3D (Pubitemid 32705726)
159. R Yamanaka SA Zullo J Ramsey, et al. 2002 Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12 J Neurosurg 97 3 611 618 12296646 1:CAS:528:DC%2BD38XnsFOjtrw%3D (Pubitemid 34994379)
160. S Zhang G Zeng DS Wilkes, et al. 2003 Dendritic cells transfected with interleukin-12 and pulsed with tumor extract inhibit growth of murine prostatic carcinoma in vivo Prostate 55 4 292 298 12712408 1:CAS:528:DC%2BD3sXkslWru7k%3D (Pubitemid 36618187)
161. RB Mailliard A Wankowicz-Kalinska Q Cai, et al. 2004 alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity Cancer Res 64 17 5934 5937 15342370 1:CAS:528:DC%2BD2cXntFClsro%3D (Pubitemid 39129387)
162. P Kalinski A Giermasz Y Nakamura, et al. 2005 Helper role of NK cells during the induction of anticancer responses by dendritic cells Mol Immunol 42 4 535 539 15607810 1:CAS:528:DC%2BD2cXhtVyktrnL (Pubitemid 39655965)
163. P Kalinski RB Mailliard A Giermasz, et al. 2005 Natural killer-dendritic cell cross-talk in cancer immunotherapy Expert Opin Biol Ther 5 10 1303 1315 16197336 1:CAS:528:DC%2BD2MXhtVGjsLrN (Pubitemid 41503042)
164. RB Mailliard S Egawa Q Cai, et al. 2002 Complementary dendritic cell-activating function of CD8 + and CD4 + T cells: helper role of CD8 + T cells in the development of T helper type 1 responses J Exp Med 195 4 473 483 11854360 1:CAS:528:DC%2BD38XhslOrt7s%3D (Pubitemid 34461300)
165. RB Mailliard YI Son R Redlinger, et al. 2003 Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function J Immunol 171 5 2366 2373 12928383 1:CAS:528: DC%2BD3sXmsVOrt70%3D (Pubitemid 37025543)
166. S Xu GK Koski M Faries, et al. 2003 Rapid high efficiency sensitization of CD8 + T cells to tumor antigens by dendritic cells leads to enhanced functional avidity and direct tumor recognition through an IL-12-dependent mechanism J Immunol 171 5 2251 2261 12928369 1:CAS:528:DC%2BD3sXmsVOrsbY%3D (Pubitemid 37025530)
167. A Wesa P Kalinski JM Kirkwood T Tatsumi WJ Storkus 2007 Polarized type-1 dendritic cells (DC1) producing high levels of IL-12 family members rescue patient TH1-type antimelanoma CD4 + T cell responses in vitro J Immunother 30 1 75 82 17198085 1:CAS:528:DC%2BD2sXjtVCl (Pubitemid 46052205)
168. P Kalinski Y Nakamura P Watchmaker A Giermasz R Muthuswamy RB Mailliard 2006 Helper roles of NK and CD8 + T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines Immunol Res 36 1-3 137 146 17337774 1:CAS:528:DC%2BD2sXisVKntrk%3D (Pubitemid 46398590)
169. A Ten Brinke ML Karsten MC Dieker JJ Zwaginga SM van Ham 2007 The clinical grade maturation cocktail monophosphoryl lipid A plus IFNgamma generates monocyte-derived dendritic cells with the capacity to migrate and induce Th1 polarization Vaccine 25 41 7145 7152 17719152 1:CAS:528: DC%2BD2sXhtFWhtLvO (Pubitemid 47464674)
170. Lee JJ, Foon KA, Mailliard RB, Muthuswamy R, Kalinski P. Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia. J Leukoc Biol;2008.
171. E Wieckowski GS Chatta RM Mailliard, et al. 2010 Type-1 polarized dendritic cells loaded with apoptotic prostate cancer cells are potent inducers of CD8(+) T cells against prostate cancer cells and defined prostate cancer-specific epitopes Prostate 71 2 125 133 20717900
172. K Gustafsson M Ingelsten L Bergqvist J Nystrom B Andersson A Karlsson-Parra 2008 Recruitment and activation of natural killer cells in vitro by a human dendritic cell vaccine Cancer Res 68 14 5965 5971 18632652 1:CAS:528:DC%2BD1cXovVCntrY%3D
173. P Dubsky H Saito M Leogier, et al. 2007 IL-15-induced human DC efficiently prime melanoma-specific naive CD8 + T cells to differentiate into CTL Eur J Immunol 37 6 1678 1690 17492620 1:CAS:528:DC%2BD2sXntVSgsLk%3D (Pubitemid 46939501)
174. LT Nguyen S Radhakrishnan B Ciric, et al. 2002 Cross-linking the B7 family molecule B7-DC directly activates immune functions of dendritic cells J Exp Med 196 10 1393 1398 12438431 1:CAS:528:DC%2BD38XovFOitbo%3D (Pubitemid 35375559)
175. S Wang J Yang J Qian M Wezeman LW Kwak Q Yi 2006 Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma Blood 107 6 2432 2439 16291589 1:CAS:528: DC%2BD28XisFOjur8%3D (Pubitemid 43345564)
176. AG Jarnicki H Conroy C Brereton, et al. 2008 Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics J Immunol 180 6 3797 3806 18322186 1:CAS:528: DC%2BD1cXisl2js7w%3D
177. MW Lipscomb L Chen JL Taylor, et al. 2009 Ectopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitro J Immunol 183 7250 7258 19915058 1:CAS:528:DC%2BD1MXhsVehsbnK
178. JR Mora MR Bono N Manjunath, et al. 2003 Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells Nature 424 6944 88 93 12840763 1:CAS:528:DC%2BD3sXltVelsLs%3D (Pubitemid 36834847)
179. JR Mora G Cheng D Picarella M Briskin N Buchanan UH von Andrian 2005 Reciprocal and dynamic control of CD8 T cell homing by dendritic cells from skin- and gut-associated lymphoid tissues J Exp Med 201 2 303 316 15642741 1:CAS:528:DC%2BD2MXot12lsQ%3D%3D (Pubitemid 40189439)
180. JR Mora UH von Andrian 2004 Retinoic acid: an educational "vitamin elixir" for gut-seeking T cells Immunity 21 4 458 460 15485623 1:CAS:528:DC%2BD2cXpvVygt7s%3D (Pubitemid 39370501)
181. P Schaerli P Loetscher B Moser 2001 Cutting edge: induction of follicular homing precedes effector Th cell development J Immunol 167 11 6082 6086 11714765 1:CAS:528:DC%2BD3MXovVCjsb8%3D (Pubitemid 33081532)
182. AJ Stagg MA Kamm SC Knight 2002 Intestinal dendritic cells increase T cell expression of alpha4beta7 integrin Eur J Immunol 32 5 1445 1454 11981833 1:CAS:528:DC%2BD38XjvFKjsb4%3D (Pubitemid 34546273)
183. W Weninger N Manjunath UH von Andrian 2002 Migration and differentiation of CD8 + T cells Immunol Rev 186 221 233 12234374 1:CAS:528:DC%2BD38XotFehtL0%3D
184. T Calzascia F Masson W Di Berardino-Besson, et al. 2005 Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs Immunity 22 2 175 184 15723806 1:CAS:528: DC%2BD2MXisFSqs78%3D (Pubitemid 40255709)
185. S Mattei MP Colombo C Melani A Silvani G Parmiani M Herlyn 1994 Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes Int J Cancer 56 6 853 857 7509778 1:CAS:528:DyaK2MXhtVGisA%3D%3D (Pubitemid 24102753)
186. M Kunz A Toksoy M Goebeler E Engelhardt E Brocker R Gillitzer 1999 Strong expression of the lymphoattractant C-X-C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma J Pathol 189 4 552 558 10629557 1:CAS:528:DC%2BD3cXltlSrtA%3D%3D
187. J Wenzel B Bekisch M Uerlich O Haller T Bieber T Tuting 2005 Type I interferon-associated recruitment of cytotoxic lymphocytes: a common mechanism in regressive melanocytic lesions Am J Clin Pathol 124 1 37 48 15923172 1:CAS:528:DC%2BD2MXmvVGnsbc%3D (Pubitemid 40944372)
188. IM Mullins CL Slingluff JK Lee, et al. 2004 CXC chemokine receptor 3 expression by activated CD8 + T cells is associated with survival in melanoma patients with stage III disease Cancer Res 64 21 7697 7701 15520172 1:CAS:528:DC%2BD2cXptFemur8%3D (Pubitemid 39446899)
189. KV Tarbell L Petit X Zuo, et al. 2007 Dendritic cell-expanded, islet-specific CD4 + CD25 + CD62L + regulatory T cells restore normoglycemia in diabetic NOD mice J Exp Med 204 1 191 201 17210729 1:CAS:528: DC%2BD2sXhtFGjt70%3D (Pubitemid 46148769)
190. S Yamazaki T Iyoda K Tarbell, et al. 2003 Direct expansion of functional CD25 + CD4 + regulatory T cells by antigen-processing dendritic cells J Exp Med 198 2 235 247 12874257 1:CAS:528:DC%2BD3sXlvVyjtb8%3D (Pubitemid 37009740)
191. MV Dhodapkar RM Steinman 2002 Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans Blood 100 1 174 177 12070024 1:CAS:528:DC%2BD38XltF2rsb8%3D (Pubitemid 35177444)
192. IJ de Vries WJ Lesterhuis JO Barentsz, et al. 2005 Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy Nat Biotechnol 23 11 1407 1413 16258544 (Pubitemid 41679393)
193. A Mackensen T Krause U Blum P Uhrmeister R Mertelsmann A Lindemann 1999 Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34 + hematopoietic progenitor cells Cancer Immunol Immunother 48 2-3 118 122 10414465 1:STN:280:DyaK1MzktFCitw%3D%3D (Pubitemid 29287296)
194. L Fong D Brockstedt C Benike L Wu EG Engleman 2001 Dendritic cells injected via different routes induce immunity in cancer patients J Immunol 166 6 4254 4259 11238679 1:CAS:528:DC%2BD3MXitVGmt70%3D (Pubitemid 32224961)
195. A Grover GJ Kim G Lizee, et al. 2006 Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes Clin Cancer Res 12 19 5801 5808 17020987 1:CAS:528:DC%2BD28XhtVartbjO (Pubitemid 44629612)
196. I Bedrosian R Mick S Xu, et al. 2003 Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8 + T-cell function in melanoma patients J Clin Oncol 21 20 3826 3835 14551301 1:CAS:528:DC%2BD2cXpsVKisLk%3D (Pubitemid 46606238)
197. T Lesimple EM Neidhard V Vignard, et al. 2006 Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients Clin Cancer Res 12 24 7380 7388 17189411 1:CAS:528:DC%2BD28XhtlCrtr%2FL (Pubitemid 46095412)
198. RS Freedman JM Bowen L Delcos, et al. 1994 Active intralymphatic immunotherapy of uterine cervical carcinoma with viral oncolysate: a pilot study Int J Gynecol Cancer 4 2 101 110 11578392 (Pubitemid 24179778)
199. T Harrer J Schwab WG Struff, et al. 1998 Intralymphatic interleukin-2 in combination with zidovudine for the therapy of patients with AIDS Infection 26 6 368 374 9861562 1:CAS:528:DyaK1MXjsVWqsg%3D%3D (Pubitemid 28542505)
200. KJ Maloy I Erdmann V Basch, et al. 2001 Intralymphatic immunization enhances DNA vaccination Proc Natl Acad Sci USA 98 6 3299 3303 11248073 1:CAS:528:DC%2BD3MXit1alsbc%3D (Pubitemid 32220840)